Astrazeneca has presented new data from several studies that confirm the security profile of the use of Dapagliflozina, marketed as 'Forxiga', as a treatment of type 2 diabetes, since no imbalances have been observed regarding the amputations of lower limbs.
This follows from the results presented in a recent meeting of the American Diabetes Association (ADA), including a real clinical practice study with the use of SGLT-2 inhibitors(ISGLT-2), including the aforementioned drug, which demonstrates a reduction of cardiovascular events.
Regarding the security analysis presented, with grouped data of 30 clinical trials phase Iib/III with dapagliflozine, no security news was observed and the incidence of adverse events was similar to that of the control groups.
Similarly, differences in the amputations of lower limbs with 8 (0.1%) and 7 (0.2%) patients in the Dapagliflozine and Control groups, respectively, were observed.
Likewise, three new analyzes have been presented that point to a significant reduction of hospitalizations for different causes and mortality in patients treated with this drug.
"SGLT-2 inhibitors are increasingly being prescribed more frequently for patients with type 2 diabetes, so it is fundamental to know perfectly the safety profile of these medications and analyze their effectiveness in real clinical practice," said the vice presidentand director of cardiovascular and metabolic diseases of the Department of Global Medicines Development of Astrazeneca, Elisabeth Björk.
